Navegar

Colección

Datos Estadísticas

Artículo

Kornblihtt, L.I.; Heller, P.G.; Correa, G.; Castañón, M.; Genoud, V.; Vassallu, P.; Sarano, J.; Kordich, L.; Molinas, F.C. "Associated thrombophilic defects in essential thrombocythaemia: Their relationship with clinical manifestations" (2004) Thrombosis Research. 112(3):131-135
La versión final de este artículo es de uso interno de la institución.
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

In order to assess the contribution of genetic and acquired thrombophilic defects in the risk of thrombosis in essential thrombocythaemia, we evaluated the prevalence of factor V Leiden, prothrombin G20210A and methylenetetrahydrofolate reductase C677T polymorphisms, homocysteinemia, protein C, protein S and antithrombin III levels, activated protein C resistance, lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein I and antiphospholipid antibodies in 60 ET patients, 17 with thrombosis and 23 with microvascular disturbances. The allele frequency of prothrombin G20210A polymorphism in ET was higher than in controls (5% vs. 0.7%, p = 0.04) while no differences were found for factor V Leiden (0.8% vs. 1.4%, p = 0.5) nor methylenetetrahydrofolate reductase C677T polymorphism (35.8% vs. 34.3%, p = 0.9). Deficiency of protein C, protein S and antithrombin III levels were not found in any patient although median protein S levels were lower than in controls (89% vs. 110%, p = 0.007). Two patients had activated protein C resistance, six harboured antiphospholipid antibodies and five had hyperhomocysteinemia. Although thrombophilic conditions were detected in one third of our patients with ET, no correlation was found between these prothrombotic factors and the development of thrombosis. Routine screening for these conditions in ET may not be justified.

Registro:

Documento: Artículo
Título:Associated thrombophilic defects in essential thrombocythaemia: Their relationship with clinical manifestations
Autor:Kornblihtt, L.I.; Heller, P.G.; Correa, G.; Castañón, M.; Genoud, V.; Vassallu, P.; Sarano, J.; Kordich, L.; Molinas, F.C.
Filiación:Secc. Hematol. Investigación, Inst. Invest. Medicas Alfredo Lanari, Universidad de Buenos Aires, Combatientes de Malvinas 3150, 1427 Buenos Aires, Argentina
Depto. de Quím. Biol., Fac. de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Argentina
e Inmunologia, Inst. Invest. Medicas Alfredo Lanari, Universidad de Buenos Aires, Argentina
Palabras clave:Essential thrombocythaemia; Factor V Leiden; Homocysteine; Prothrombin G20210A; Thrombophilic defects; Thrombosis; 5,10 methylenetetrahydrofolate reductase (FADH2); acetylsalicylic acid; activated protein C; anagrelide; antithrombin III; beta2 glycoprotein 1 antibody; blood clotting factor 5 Leiden; cardiolipin antibody; homocysteine; hydroxyurea; lupus anticoagulant; phospholipid antibody; protein C; protein S; prothrombin; activated protein C resistance; adolescent; adult; aged; antibody blood level; article; cardiovascular risk; clinical feature; controlled study; disease association; DNA polymorphism; female; gene frequency; genetic risk; heredity; homocystinuria; human; hyperhomocysteinemia; major clinical study; male; microangiopathy; priority journal; protein blood level; protein deficiency; school child; thrombocythemia; thrombophilia; thrombosis; Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antithrombin III; Child; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Protein C; Prothrombin; Quinazolines; Reference Values; Thrombocythemia, Hemorrhagic; Thrombophilia
Año:2004
Volumen:112
Número:3
Página de inicio:131
Página de fin:135
DOI: http://dx.doi.org/10.1016/j.thromres.2003.11.012
Título revista:Thrombosis Research
Título revista abreviado:Thromb. Res.
ISSN:00493848
CODEN:THBRA
CAS:5,10 methylenetetrahydrofolate reductase (FADH2), 9028-69-7; acetylsalicylic acid, 493-53-8, 50-78-2, 53663-74-4, 53664-49-6, 63781-77-1; anagrelide, 68475-42-3; antithrombin III, 90170-80-2; homocysteine, 454-28-4, 6027-13-0; hydroxyurea, 127-07-1; protein C, 60202-16-6; prothrombin, 9001-26-7; anagrelide; Antithrombin III, 9000-94-6; Hydroxyurea, 127-07-1; Platelet Aggregation Inhibitors; Protein C; Prothrombin, 9001-26-7; Quinazolines
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00493848_v112_n3_p131_Kornblihtt

Referencias:

  • Murphy, S., Diagnostic criteria and prognosis in Polycythemia Vera and Essential Thrombocythemia (1999) Semin. Hematol., 36, pp. 9-13
  • Tefferi, A., Murphy, S., Current opinion in essential thrombocythemia: Pathogenesis, diagnosis and management (2001) Blood Rev., 15, pp. 121-131
  • Cortelazzo, S., Viero, P., Finazzi, G., D'Emilio, A., Rodeghiero, F., Barbui, T., Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia (1990) J. Clin. Oncol., 8, pp. 556-562
  • Watson, K.V., Key, N., Vascular complications of essential thrombocythemia: A link to cardiovascular risk factors (1993) Br. J. Haematol., 83, pp. 198-203
  • Kornblihtt, L.I., Vassallu, P.S., Heller, P., Molinas, F.C., Diez años de experiencia con anagrelide en el tratamiento de la trombocitemia esencial (2002) Medicina, 62, pp. 231-236
  • Bertina, R.M., Koeleman, B.P.C., Koster, T., Rosendaal, F.R., Dirven, R.J., De Ronde, H., Mutation in blood coagulation factor V associated with resistance to activated protein C (1994) Nature, 369, pp. 64-67
  • Poort, S.R., Rosendaal, F.R., Reitsma, P.H., Bertina, R.M., A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis (1996) Blood, 88, pp. 3698-3703
  • Froost, P., Blom, H.J., Milos, R., Goye Ten, P., Shepard, C.A., Mathews, R.G., A candidate genetic risk factor for vascular disease: A common mutation in methylenentetrahydrofolate reductase (1995) Nat. Genet., 10, pp. 111-113
  • Gisslinger, H., Rodeghiero, F., Ruggieri, M., Fard, N.H.V., Mannhalter, C., Papagiannopoulis, M., Homocysteine levels in polycythemia vera and essential thrombocythemia (1999) Br. J. Haematol., 105, pp. 551-555
  • Amitrano, L., Guardasciones, M.A., Ames, P.R.J., Maargaglione, M., Antinolfi, I., Iannaccone, L., Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: Relationship with splachnic vein thrombosis and arterial disease (2003) Am. J. Hematol., 72, pp. 75-81
  • Wieczorek, I., Mac Gregor, I.R., Ludlam, C.A., Low proteins C and S and activation of fibrinolysis in treated in essencial thombocythemia (1995) Am. J. Hematol., 49, pp. 277-281
  • Jensen, M., Brown, P., Thorsen, S., Hasselbalch, H., Frequent occurrence of anticardiolipin antibodies, factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders (2002) Am. J. Hematol., 69, pp. 185-191
  • Bucalossi, A., Marotta, G., Bigazzi, C., Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis (1996) Am. J. Hematol., 52, pp. 14-20
  • Harrison, C., Donohoe, S., Carr, P., Dave, M., MacKie, I., MacHin, S., Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis (2002) Thromb. Haemost., 87, pp. 802-807
  • Afshai-Kharghan, V., López, J.A., Gray, L.A., Hemostatic gene polymorphisms and the prevalence of thrombohemorrahagic complications in polycythemia vera and essential thrombocythemia (2001) Blood, 98, pp. 471a. , [abstract]
  • Ruggieri, M., Gisslinger, H., Tosetto, A., Rintelen, C., Mannhalter, C., Pabinger, I., Factor V Leiden mutation carriership and venus thromboembolism in Polycythemia Vera and Essential Thrombocythemia (2002) Am. J. Hematol., 71, pp. 1-6
  • Genoud, V., Castañon, M., Annichino-Bizzacchi, J., Korin, J., Kordich, L., Prevalence of three prothrombotic polymorphisms: Factor V G1691A, factor II G20210A and methylenetetrahydrofolate reductase (MTHFR) C677T in Argentina (2000) Thromb. Res., 100, pp. 127-131
  • Bratström, L., Wilcken, D.E.L., Öhrvik, J., Brudin, L., Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. the result of a meta-analysis (1998) Circulation, 98, pp. 2520-2526
  • Lane, D.A., Grant, P.J., Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease (2000) Blood, 95, pp. 1517-1532

Citas:

---------- APA ----------
Kornblihtt, L.I., Heller, P.G., Correa, G., Castañón, M., Genoud, V., Vassallu, P., Sarano, J.,..., Molinas, F.C. (2004) . Associated thrombophilic defects in essential thrombocythaemia: Their relationship with clinical manifestations. Thrombosis Research, 112(3), 131-135.
http://dx.doi.org/10.1016/j.thromres.2003.11.012
---------- CHICAGO ----------
Kornblihtt, L.I., Heller, P.G., Correa, G., Castañón, M., Genoud, V., Vassallu, P., et al. "Associated thrombophilic defects in essential thrombocythaemia: Their relationship with clinical manifestations" . Thrombosis Research 112, no. 3 (2004) : 131-135.
http://dx.doi.org/10.1016/j.thromres.2003.11.012
---------- MLA ----------
Kornblihtt, L.I., Heller, P.G., Correa, G., Castañón, M., Genoud, V., Vassallu, P., et al. "Associated thrombophilic defects in essential thrombocythaemia: Their relationship with clinical manifestations" . Thrombosis Research, vol. 112, no. 3, 2004, pp. 131-135.
http://dx.doi.org/10.1016/j.thromres.2003.11.012
---------- VANCOUVER ----------
Kornblihtt, L.I., Heller, P.G., Correa, G., Castañón, M., Genoud, V., Vassallu, P., et al. Associated thrombophilic defects in essential thrombocythaemia: Their relationship with clinical manifestations. Thromb. Res. 2004;112(3):131-135.
http://dx.doi.org/10.1016/j.thromres.2003.11.012